Mainstream Capital Management »

Allogene Therapeutics shares owned by Mainstream Capital Management

Quarter-by-quarter ownership of Allogene Therapeutics (ALLO) shares owned by Mainstream Capital Management from 13F filings

Historical chart of Mainstream Capital Management investment in Allogene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Allogene Therapeutics held by Mainstream Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allogene Therapeutics by Mainstream Capital Management

Quarter filed Position value Share count Share price at filing
2026-09-30 $881 551 1.60
2024-12-31 $16k 7.5k 2.13

More positions owned by Mainstream Capital Management

Jpmorgan Ultra-short Income Etf Etf (JPST)
Apple Stock (AAPL)
Goldman Sachs Ultra Short Bond Etf Etf (GSST)
Amazon Stock (AMZN)
Nvidia Corporation Stock (NVDA)
Alphabet Inc Cap Stk Cl C Stock (GOOG)
Meta Platforms Inc Cl A Stock (META)
Crowdstrike Hldgs Inc Cl A Stock (CRWD)
Microsoft Corp Stock (MSFT)
Ishares Core S&p 500 Etf Etf (IVV)
Palo Alto Networks Stock (PANW)
Alphabet Inc Cap Stk Cl A Stock (GOOGL)
Ishares Russell 1000 Growth Etf Etf (IWF)
Jpmorgan Chase & Co Stock (JPM)
Berkshire Hathaway Inc Del Cl B Stock (BRK.B)

View all positions for Mainstream Capital Management

Top funds holding Allogene Therapeutics

BlackRock
Frazier Life Sciences Management
Pfizer
State Street Corporation
Tpg Gp A
Sio Capital Management
PRIMECAP Management Company
Vanguard Capital Management
FMR
Citadel Advisors
Two Sigma Investments
Geode Capital Management
Goldman Sachs Group
Marshall Wace
Patient Square Capital

View all funds holding Allogene Therapeutics